BridgeMD
RESET C2
EU CTIS ID: 2026-525214-62-00
What this study is testing
Proportion of patients with clinical complete response (cCR) at the end of pembrolizumab treatment
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinical UICC stage I-III dMMR colon adenocarcinoma
- Age ≥18 years
- Written informed consent
- Indication for elective curative-intent surgery
You likely can't join if
- Patients deemed to be non-surgical candidates by MDT
- Patients with a need for emergent surgery due to tumour obstruction
- Contraindications to pembrolizumab, assessed by the study investigator(s)
- Any serious or uncontrolled medical disorder, including other malignant disease, that may increase the risk associated with participation or drug administration.
- Patients with colonic stents
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.